Indian generic drug maker Dr Reddy's Laboratories on Wednesday announced the launch of antiviral drug Avigan (favipiravir) tablets, currently being manufactured by Japanese drug giant Fujifilm Toyama Chemical Co, for potential treatment of mild to moderate Covid-19. This comes a month after Dr Reddy’s Laboratories partnering with Fujifilm Toyama Chemical Co and Global Response Aid (GRA) for development, manufacture and sale of Avigan. The agreement that the Hyderabad headquartered generic drug maker entered into grants it exclusive rights for India while it grants both Dr Reddy’s and GRA rights to develop, sell and distribute Avigan in all countries other than Japan, China and Russia.

Announcing the launch of Avigan in India, Dr Reddy’s management said it is currently taking up studies with GRA in Kuwait and is in talks with various regulators in across the globe including the USFDA to seek fast-track approvals for Avigan. The generic drug maker hopes to complete the multi-ethnic trials on over 700 patients during the 10-12 weeks to submit them to various global drug regulators. Dr Reddy’s is currently taking up contract manufacturing of Remdesivir injection being administered intravenously in a hospital for treatment of severe Covid-19 under the license from Gilead Sciences and plans to launch its own product in India by September first week.

Indian generic drug maker Dr Reddy's Laboratories on Wednesday announced the launch of antiviral drug Avigan (favipiravir) tablets, currently being manufactured by Japanese drug giant Fujifilm Toyama Chemical Co, for potential treatment of mild to moderate Covid-19. This comes a month after Dr Reddy’s Laboratories partnering with Fujifilm Toyama Chemical Co and Global Response Aid (GRA) for development, manufacture and sale of Avigan. The agreement that the Hyderabad headquartered generic drug maker entered into grants it exclusive rights for India while it grants both Dr Reddy’s and GRA rights to develop, sell and distribute Avigan in all countries other than Japan, China and Russia.

Announcing the launch of Avigan in India, Dr Reddy’s management said it is currently taking up studies with GRA in Kuwait and is in talks with various regulators in across the globe including the USFDA to seek fast-track approvals for Avigan. The generic drug maker hopes to complete the multi-ethnic trials on over 700 patients during the 10-12 weeks to submit them to various global drug regulators. Dr Reddy’s is currently taking up contract manufacturing of Remdesivir injection being administered intravenously in a hospital for treatment of severe Covid-19 under the license from Gilead Sciences and plans to launch its own product in India by September first week.